CeQur Simplicity has received 2 recent FDA clearances that expand its clinical utility and patient applicability.  These clearances will enable an expansion of the CeQur Simplicity portfolio of products that will allow healthcare providers more flexibility to treat a wider array of patients.

• Up to 7-Day Wear: CeQur Simplicity is now FDA-cleared for up to seven continuous days of wear, extended from the previous four-day maximum wear duration. For many patients, this will further reduce the burden of their mealtime insulin dosing regimens by enabling fewer device changes for a given volume of insulin.
• 1-Unit Dosing: FDA’s clearance of an additional 1U dosing device gives clinicians a more precise titration tool, enabling more individualized insulin regimens. This is particularly relevant for patients requiring tighter glycemic control or those having lower mealtime insulin needs.